



# Supplementary information

## 1 Supplementary Figures



**Supplementary Figure 1: A tumor's priming rate affects the location of a tipping point.**

**(A)** In the absence of T cell priming, survival is only determined by the tumor growth rate. Logically, a tipping point cannot be present. Priming rate  $\alpha = 0$ . **(B-D)** Higher T cell priming rates lead to increased availability of cytotoxic T cells. As a result, despite a similar killing rate, the augmented T cell pool can clear tumors with a higher priming rate more easily. These findings are visible as a shifting tipping point in the phase diagrams. As stated in the Methods, a priming rate of 0.0025 is mechanistically plausible and, therefore, selected as the default priming rate (indicated with a \*). Parameter values for low and high priming rates are  $\alpha = 0.00125$  and  $\alpha = 0.025$ , respectively.



**Supplementary Figure 2: Tumor-immune dynamics determine the clinical outcome of patients in close proximity to a tipping point.**

## 2 Supplementary Tables

**Supplementary Table 1: Simulation parameters of Figure 1**

| Panel   | Simulation parameters |
|---------|-----------------------|
| Overall | $\rho = 1$            |
| B       | $\xi = 0.005$         |
| C       | $\xi = 0.00025$       |
| D       | $\xi = 0.0005$        |

Supplementary Table 2: Simulation parameters of Figure 2

| Panel | Simulation parameters   |
|-------|---|
| A     | Main: $\rho$ = range from 0 to 7, $\xi$ = 0.005<br><br>Inset 1: $\rho$ = 2, $\xi$ = 0.005<br><br>Inset 2: $\rho$ = 5.5, $\xi$ = 0.005 |
| B     | Main: $\rho$ = 6, $\xi$ = range from 0 to 0.005<br><br>Inset 1: $\rho$ = 6, $\xi$ = 0.005<br><br>Inset 2: $\rho$ = 6, $\xi$ = 0.035   |
| C     | $\rho$ = range from 0 to 7<br>$\xi$ = range from 0 to 0.05  |

Supplementary Table 3: Simulation parameters of Figure 3

| Panel | Simulation parameters  |
|-------|--|
| B/C   | Main: $\rho$ = 2, $\xi$ = 0.001<br><br>Variation in treatment effect and treatment duration are indicated on the x-axes of the figures.  |
| D     | Baseline values for the T cell killing rate were fixed at $\xi$ = 0.0025.<br>Baseline values for the tumor growth rate ( $\rho$ ) were sampled from a normal distribution: $\rho \sim N(2.5, 1)$ . We included only patients ( $n$ = 20) with clinically evident tumors. |
| E     | Baseline values for the tumor growth rate were fixed at $\rho$ = 2.5.<br>Baseline values for the T cell killing rate ( $\xi$ ) were sampled from a uniform distribution: $\xi \sim U(0, 0.005)$ . We included only patients ( $n$ = 20) with clinically evident tumors.  |

Supplementary Table 4: Simulation parameter of Figure 4

| Panel   | Simulation parameters  |
|---------|--|
| Overall | Treatment effect = $\xi$ * 12.5  |
| A       | $\rho$ = 2, $\xi$ = 0.001, stochasticity tumor growth rate = 0.3   |
| B       | $\rho$ = 2, $\xi$ = 0.001, stochasticity T cell killing rate = 0.3   |
| C       | Baseline values were sampled from two normal distributions: <ul style="list-style-type: none"> <li><math>\rho \sim N(2.5, 1)</math></li> <li><math>\xi \sim N(0.0025, 0.001)</math></li> </ul> We select patients ( $n$ = 12) with clinically evident tumors and rejected all patients in which tumors did not exceed the diagnosis threshold.<br><br>Stochasticity tumor growth rate = 0.3, stochasticity T cell killing rate = 0.3 |
| D       | $\rho$ = range from 0 to 7, $\xi$ = 0.005, stochasticity tumor growth rate = 0.3   |
| E       | $\rho$ = 6, $\xi$ = range from 0 to 0.05, stochasticity T cell killing rate = 0.3  |

Supplementary Table 5: Simulation parameters of Figure 5

| Panel   | Simulation parameters  |
|---------|--|
| Overall | Baseline values sampled from two uniform distributions: <ul style="list-style-type: none"> <li><math>\rho \sim U(4, 5)</math></li> </ul> |

|   |  |
|---|--|
|   | <ul style="list-style-type: none"> <li><math>\xi \sim U(0.015, 0.025)</math></li> </ul> <p>Simulations where the tumor did not become clinically apparent (i.e., did not reach a size of <math>65 \times 10^8</math> tumor cells) were not included in the analysis.</p> |
| A | Treatment effect = $\xi \times 4$  |
| B | <p>Treatment effect = <math>\xi \times 4</math></p> <p>Stochasticity in tumor growth rate = 0.05</p> <p>Stochasticity in T cell killing rate = 0.05</p>  |

*Supplementary Table 6: Baseline characteristics of retrospective validation cohort.*

| Overall (N=58)                   |                   |
|----------------------------------|-------------------|
| <b>Gender</b>                    |                   |
| Female                           | 21 (36.2%)        |
| Male                             | 37 (63.8%)        |
| <b>Age (years)</b>               |                   |
| Median [Min, Max]                | 51.0 [19.0, 76.0] |
| <b>Breslow thickness (mm)</b>    |                   |
| Median [Min, Max]                | 2.65 [0.7, 13.0]  |
| <b>M stage at inclusion</b>      |                   |
| M1a                              | 13 (22.4%)*       |
| M1b                              | 14 (24.1%)        |
| M1c                              | 31 (53.4%)        |
| <b>LDH (U/L)</b>                 |                   |
| Median [Min, Max]                | 388 [228, 1830]   |
| <b>Time to M stage (months)</b>  |                   |
| Median [Min, Max]                | 29.3 [0, 137]     |
| <b>Overall Survival (months)</b> |                   |
| Median [Min, Max]                | 8.92 [1.15, 130]  |

\* Includes one irresectable stage III melanoma patient.

*Supplementary Table 7: Cox proportional hazard models on validation cohort.*

| Model           | N  | HR*  | 95% CI         | Wald statistic   | Likelihood ratio test |
|-----------------|----|------|----------------|------------------|-----------------------|
| LDH             | 58 | 6.92 | (2.93 - 16.31) | $p = 1.01e^{-5}$ | $p = 4e^{-5}$         |
| I/P ratio       | 58 | 0.64 | (0.53 - 0.77)  | $p = 2.07e^{-6}$ | $p = 3.7e^{-7}$       |
| LDH + I/P ratio | 58 |      |                |                  | $p = 9.3e^{-10}$      |
| LDH             |    | 7.80 | (2.98 - 20.37) | $p = 2.8e^{-5}$  |                       |
| I/P ratio       |    | 0.65 | (0.55 - 0.78)  | $p = 4.4e^{-6}$  |                       |

\* Before analysis, all predictors were log-transformed.